10 results about "Cholesterol biosynthesis" patented technology

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

The subject matter described herein relates to compounds of Formula A and pharmaceutically acceptable salts thereof that promote myelination, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelination-related conditions.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

This invention discloses a genetically engineered strain of *Saccharomyces cerevisiae* and its application in cholesterol synthesis. The strain was obtained through multiple genetic engineering steps, starting with *Saccharomyces cerevisiae* SquP1: DHCR24 gene was integrated at the YPL062W site to achieve 7-dehydrocholesterol synthesis; the ERG6 promoter was replaced with the ERG7 promoter and the DWF5 gene was integrated to achieve cholesterol synthesis; the TGL3, TGL4, and ROX1 genes were knocked out to enhance cholesterol accumulation; the FLX1 and ZWF1 genes were integrated to strengthen cofactor supply; the HXK1 promoter was replaced and the ERG11 gene was integrated to optimize the synthesis pathway; and auxotrophic genes were reintroduced to obtain the CC37N strain. This strain achieved a maximum yield of 6.23 g / L in a 5L bioreactor fermentation, providing an excellent strain for efficient cholesterol biosynthesis.

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and / or maturation includes administering to the cell an effective amount of an agent that enhances and / or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

The present disclosure provides methods of generating extracellular vesicles as well as methods of increasing extracellular vesicle production from producer cells that exhibit reduced gene and / or protein function in the cholesterol biosynthetic pathway wherein the producer cells are contacted with cholesterol.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating lung cancer, and belongs to the technical field of biological medicine. In order to solve the problem that in the prior art, when a single drug of terbinafine is used for treating lung cancer, SQLE feedback is increased, the invention provides an ellagic acid and terbinafine composition which is composed of ellagic acid and terbinafine in a mass ratio of 4: 7. The pharmaceutical composition provided by the invention is used for preparing a medicine for treating lung cancer, and the composition can inhibit SQLE in a targeted manner through dual mechanisms, block a cholesterol biosynthesis pathway and inhibit tumor growth; through the synergistic effect of the terbinafine and the ellagic acid, the anti-tumor effect is remarkably improved, adverse reactions such as metabolic disorder caused by the terbinafine can be reduced, the drug toxicity of the ellagic acid is reduced, and the drug resistance is effectively prevented. The pharmaceutical composition is developed on the basis of commercially available drugs, has the dual advantages of enhancing the curative effect and improving the safety, and provides a more optimized treatment scheme for lung cancer treatment.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating lung cancer, belonging to the field of biomedical technology. To address the problem of increased SQLE feedback during terbinafine monotherapy for lung cancer in existing technologies, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 4:7. The pharmaceutical composition provided by this invention is used to prepare drugs for treating lung cancer. This composition can target and inhibit SQLE through a dual mechanism, blocking cholesterol biosynthesis pathways and inhibiting tumor growth; the synergistic effect of the two significantly enhances the anti-tumor effect, while also reducing adverse reactions such as metabolic disorders caused by terbinafine, mitigating the drug toxicity of ellagic acid itself, and effectively preventing the development of drug resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of enhanced efficacy and improved safety, providing a more optimized treatment plan for lung cancer.

The present disclosure relates to benzimidazolyl urea derivatives and pharmaceutical uses thereof. The benzimidazolyl urea derivative exhibits an excellent effect in the treatment and prevention of pathological conditions caused by excess glucocorticoids by inhibiting adrenal corticosteroid production and cholesterol biosynthesis, and can be used for the prevention and treatment of endogenous hypercortisolism.

The invention discloses an application of high capsaicin II in preparation of a targeted kinin KIF11 anti-tumor drug, the high capsaicin II is directly combined with a Tyr-104 / Thr-300 / Arg-355 site of KIF11 and stabilizes kinin KIF11, the kinin KIF11 stabilizes cholesterol biosynthesis and induces centrosome amplification, and the high capsaicin II and kinin KIF11 mediated centrosome separation synergistically drive multipolar splitting, so that the high capsaicin II can be used for preparing the targeted kinin KIF11 anti-tumor drug. And finally, ferroptosis is triggered. According to the invention, the toxicity of the traditional KIF11 inhibitor is overcome, the tumor specific induction of ferroptosis is realized, and the indications of the targeted therapy of the kinin KIF11 are expanded.